Avingtrans plc (AIM: AVG), a designer and manufacturer of critical systems for the energy, medical and industrial sectors, announced on Monday that its subsidiary Adaptix Limited has received 510(k) clearance from the U.S. Food and Drug Administration for its orthopaedic 3D imaging product, the Adaptix Ortho350.

The Ortho350 is a compact, mobile, low-dose 3D Digital Tomosynthesis imaging system designed for point-of-care use. It provides rapid, cost-effective 3D X-ray imaging for upper and lower extremities with substantially lower radiation exposure than traditional CT systems. The product delivers improved image clarity over 2D X-ray systems, enhancing diagnostic precision and clinical efficiency.

Adaptix has already commercialised its core imaging technology in veterinary and industrial markets through the Adaptix VetSA3D and Adaptix NDT3D systems. FDA clearance enables entry into the US human healthcare imaging market, representing a major milestone in Adaptix's strategy to advance point-of-care radiology.

Avingtrans continues to operate across a diversified portfolio of engineering businesses, including Hayward Tyler, Energy Steel, Stainless Metalcraft, Booth Industries, Ormandy Group, Slack & Parr, Composite Products, Adaptix and Magnetica, serving clients globally across the energy, medical and industrial sectors.